Alto Neuroscience (ANRO) Preferred Stock Liabilities (2023)

Alto Neuroscience has reported Preferred Stock Liabilities for 1 years, with the latest figure at $141.5 million in Q4 2023.

• Quarterly Preferred Stock Liabilities changed N/A year-over-year to $141.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $141.5 million (changed N/A YoY) and the FY2023 annual result came in at $141.5 million, changed N/A from the prior year.
• Preferred Stock Liabilities climbed to $141.5 million in Q4 2023 per ANRO's latest filing, from $97.1 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $141.5 million in Q4 2023 and troughed at $97.1 million in Q1 2023.